Business Wire

Trivver Launches Token Sale to Encourage Adoption and Development of Extended Reality Technology

Jaa

Trivver, the premiere advertising exchange for Extended Reality (XR) environments including 3D, virtual reality, mixed reality and augmented reality, today announced that it will launch the sale of up to 100 million Trivver Tokens (TRVR) to accelerate the adoption, commercialization and monetization of XR technology across devices and industries for all stakeholders in the ecosystem – including content publishers, advertisers, brands, agencies and consumers.

Current 2D advertising tactics like pop-ups, banners, video and interstitials are highly disruptive to immersive XR experiences, leading to limited advertiser adoption of XR and reduced monetization opportunities for XR developers and publishers. Placing ads organically within the natural settings of XR environments is the answer, but the current processes that developers, publishers and advertisers use to execute this strategy is tedious and costly, as ads and objects need to be manually resized to fit each unique location. With Trivver’s suite of patented technology, including its core Smart Object Technology, developers are able to create and deliver native advertising directly into XR environments. This approach enables advertisers to create contextual, integrated XR ad campaigns to engage consumers in a unique and impactful way and gives publishers the opportunity to efficiently monetize their XR content.

“We believe in the exponential possibilities of XR and in the profound, lasting and global impact of this technology,” said Joel LaMontagne, CEO of Trivver. “We are passionate about driving XR adoption among consumers and within the enterprise. Our goal is to enable publishers and developers in the XR space to fund themselves through advertising and encourage the improvement of technology that enhances XR experiences for consumers. We’re also making it easier for advertisers to promote their brand in the XR space through seamless product placement – delivering relevant and interesting content to engage their users.”

In order to drive XR adoption and momentum, Trivver launched its pre-sale of TRVR tokens, which can be purchased with a bonus until June 5, 2018. The public token sale begins on June 8, 2018 and will close on July 7, 2018. The public sale will aim to raise $35 million, with the pre-sale accounting for up to $5 million.

Token Sale Details:

  • Under the terms of the sale, 1 ETH is equivalent to 750 TRVR (1 TRVR ~ 0.00133 ETH) and a hard cap of 100 million TRVR tokens are available for purchase of the finite supply of 200 million total TRVR.
  • All available TRVR will be issued during the distribution period, of which, 50 percent will be allocated to the public and 50 percent will be allocated to the reserve to be held by the company and used to stimulate growth in the Trivver XR advertising ecosystem by rewarding participants with TRVR.
  • All TRVR not distributed will be burned.

TRVR is the currency for the Smart Object Economy. Trivver’s patented Branded Smart Objects (BSOs) are 3D objects with product information (SKU data, coupons, social media links etc.) that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment. Trivver’s BSOs send valuable viewability and user engagement metrics back to the advertiser that will result in the best ROI.

Trivver launched its token sale in order to accelerate the build out of its Smart Objects catalog and will incentivize developers to participate through a system of rewards and payments of TRVR. Developers can earn TRVR for building and adding smart objects to the catalog. They can also use TRVR to list the smart object in Trivver’s inventory and establish authorship of the object. As the author, developers will receive royalties paid in USD from Trivver whenever revenues are generated by the smart object - from a publisher using it to build XR content or by an advertiser using it for future XR ad campaigns.

The Trivver platform is currently in beta and the company has already seen significant interest, announcing upcoming pilot programs in collaboration with WayFair and Cannon.

To learn more about Trivver and to participate in the token sale, visit: https://www.trivver.com/tokensale or join the conversation on Telegram to speak directly with the project’s founders and developers: https://t.me/trivvertokensale. Download the token sale whitepaper at: https://www.trivver.com/docs/Trivver_Whitepaper.pdf.

About Trivver

Trivver is the premiere advertising exchange for Extended Reality (XR) environments – 3D, virtual reality, mixed reality and augmented reality. The Trivver platform makes creating and deploying 3D interactive branded objects easier, allowing brands to programmatically execute targeted, impactful and scalable XR campaigns.

Trivver’s revolutionary, patented Branded Smart Objects (BSOs) are 3D objects that exist as ads within the natural setting of 3D environments. BSOs are designed to autoscale and render in any XR platform – enabling advertisers to seamlessly and organically engage multiple audiences without additional development time or financial investment.

The Trivver XR Ad Exchange (XRAE) is a programmatic solution that lets advertisers create, run and monitor a highly targeted XR ad campaign in near real time, on mobile apps and desktop applications. Trivver enables publishers to monetize XR environments with branded content that is native and organic – eliminating pop-ups, banners and interstitials that are disruptive to user experience. The Trivver platform facilitates an organic relationship between brand and consumer.

Contact information

Affect
Nicole Sullivan, 212-398-9680
trivver@affect.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Ultra-Low Power Lattice sensAI Leads Mass Market Enablement of Artificial Intelligence in Edge Devices21.5.2018 15:00Tiedote

Lattice Semiconductor Corporation (NASDAQ: LSCC) today unveiled Lattice sensAI™ – a complete technology stack combining modular hardware kits, neural network IP cores, software tools, reference designs and custom design services – to accelerate integration of machine learning inferencing into broad market IoT applications. With solutions optimized for ultra-low power consumption (under 1 mW–1 W), small package size (5.5 mm2 –100 mm2), interface flexibility (MIPI® CSI-2, LVDS, GigE, etc.), and high-volume pricing (~$1-$10 USD), Lattice sensAI stack fast-tracks implementation of edge computing close to the source of data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005011/en/ (Graphic: Business Wire) “Lattice sensAI addresses the unmet need for flexible, low cost, ultra-low power AI silicon solutions suited for rapid deployment across a wide range of emerging, mass market IoT applications,” said Deepak Boppana, senior

NioCorp Awards Contract to Rockwell Automation on Groundbreaking Critical Minerals, Mining and Processing Facility in Nebraska21.5.2018 15:00Tiedote

NioCorp Developments Ltd. (TSX: NB, OTCQX: NIOBF), a developer of superalloy metals, has awarded a major contract to Rockwell Automation (NYSE: ROK) to engineer, design and procure process automation and instrumentation for NioCorp’s proposed critical minerals, mining and processing facility in Elk Creek, Nebraska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005228/en/ Three superalloy metals – niobium, scandium and titanium – are expected to be produced by the facility as early as 2021. These critical materials are used in the aerospace, defense, automotive, clean energy, commercial aviation and mega-infrastructure sectors. Generally, these superalloys enable increased strength and lighter weight in transportation and other systems, leading to better fuel efficiency and lower greenhouse gas and other air emissions, according to NioCorp. “We selected Rockwell Automation and its partners to automate our process equip

Biosimilars could facilitate early access to life changing biological treatments for patients says Celltrion Healthcare21.5.2018 14:27Tiedote

At the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Celltrion Healthcare today advocated for healthcare systems to introduce biologics earlier in a patient’s treatment regimen in order to improve clinical outcomes. Several studies show that the early introduction of biologics can bring greater clinical benefit to patients.1,2,3,4,5,6 However, only a limited number of patients have access to biological treatment due to the high-cost of biologics and current reimbursement policies determined by pharmacoeconomic evaluations. Since the introduction of biosimilars, the overall cost of biological treatments has reduced in Europe, allowing an increased number of patients to access this important treatment option earlier in their course of treatment.7 Professor Jørgen Jahnsen said, “For the treatment of inflammatory bowel disease, biological treatments are proven to be the most efficacious medical therapy and their ea

Dole’s Joint Venture Recycling Company Celebrates 25 Years21.5.2018 14:00Tiedote

Dole Food Company announced today that Recyplast S.A., an innovative plastic recycling company based in Costa Rica and with joint ownership including a subsidiary of Dole Fresh Fruit, recently surpassed 25 years in its mission to dramatically reduce and reuse agricultural waste. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180521005160/en/ Raul Martinez (right), General Manager of Dole Standard Fruit de Costa Rica, receives a plaque from Jose Miguel Ramirez, General Manager of Recyplast, in recognition of the contribution of Dole's banana plantations in the correct handling, storage, and provision of field plastic waste. The plastic recycling facility pioneered the collection of field plastics after use in banana growing operations in Costa Rica. This reuse and recycling process includes reclamation of plastic bags that protect bananas from weather and insects, as well as the collection of plastic twine used to prop the ba

ViiV Healthcare Receives EU Marketing Authorisation for Juluca (dolutegravir/rilpivirine), the First 2-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV21.5.2018 13:11Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Commission has granted marketing authorisation for Juluca (dolutegravir 50mg/rilpivirine 25mg) for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.1 Juluca is a 2-drug regimen of dolutegravir (ViiV Healthcare), the most widely prescribed integrase inhibitor worldwide,2 and rilpivirine (Janssen Sciences Ireland UC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson).1 Deborah Waterhouse, CEO ViiV Healthcare said, “The European Commission Decision for Juluca is very positive news for people living with

Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-121.5.2018 13:06Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission has granted marketing authorisation for JULUCA® (dolutegravir 50mg [ViiV Healthcare]/rilpivirine 25mg [Janssen Sciences Ireland UC]).1 ViiV Healthcare, as the marketing authorisation holder, will market dolutegravir/rilpivirine in all countries in the European Union and European Economic Area. Dolutegravir/rilpivirine is the first two-drug regimen, once-daily, single-pill for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor (INI).1 “The European Commission Decision for dolutegravir/rilpivirine marks a significant milestone in our 25-year commitment to make HIV history,” said Brian Woo

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme